Clinical Trial

Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM

Study acronym: VVSHIP
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This prospective study aims to investigate the efficacy and safety of peritumoral injection of the oncolytic virus H101 in combination with stereotactic body radiotherapy (SBRT), PD-1 monoclonal antibody, chemotherapy, and targeted therapy for the treatment of patients with unresectable, microsatellite stable/mismatch repair proficient (MSS/pMMR) colorectal adenocarcinoma liver metastases. The ultimate goal is to provide high-level evidence-based medical support for this combined modality approach.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-25.
Trial Details
NCT Number NCT07381309
Lead Sponsor Jun Huang
Conditions CRC, Liver Metastasis Colon Cancer
Enrollment 114 participants
Start Date 2026-06-01
Primary Completion 2028-02-01 (estimated)
Study Completion 2029-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-28